November 2018 Vol 9, NO 11
Susan G. Häag, PhD, MS, Tricia Strusowski, RN, MS, Alyssia Crews, MBA, Beth High, MSN, RN, OCN, CBCN, CN-BN
Patient navigation has been shown to improve patient engagement and enrollment in clinical trials and increase supportive cancer care.
Employee engagement is a key element of success among businesses and organizations.
Offering patients access to oncology navigation is not only recommended, it is also a requirement for certification of oncology programs endorsed by 2 national organizations.
The orientation/onboarding process is neither standardized nor well understood across the oncology navigation industry.
There is extensive literature in change and transition management in leadership but limited literature from a non-managerial or navigator’s point of view.
Benefits of a Multidisciplinary Survivor Clinic in Addressing Quality of Life After Cancer Treatment
Laura Beaupre, RN, BSN, OCN, CN-BN, Jane Zubia, RN, OCN, CN-BN, Kathleen Sevedge, RN, MA, AOCN, Eileen Steirer, Alyssa Pauls, RN, BSN, OCN, Cynthia Smith, RN, BSN, OCN, MA, Maritza Chicas, RN, BSN, OCN, Jeanne Kenna, RN, OCN, CRNI, Angela Miller, RN, BSN, OCN, MEd, Raizalie Roman, RN, BSN, OCN
“Care of the cancer survivor should include prevention, surveillance, assessment of late effects and intervention for consequences of cancer and treatment.”
Kay Hankins, RN, Jolene Hetsler, RN, ONS, Cynthia Kuhn, RN, CBCN, MaryAnn Pedersen, RN, Beth Matthews, MSN, RN, OCN
Advance care planning (ACP) is central to patient-centered care and improves alignment between patient preferences and care received at end-of-life.
A recent needs assessment for Camden County, NJ, shows that residents’ compliance with cancer screening recommendations for colon (65%), breast (73%), and cervical (74%) cancers does not meet Healthy People 2020 guidelines.
Palliative care is a collaborative approach that improves quality of life for patients and families but is often provided too late.
Carol Del Campo, RN, BSN, OCN, Kevin Schreffler, MSN, RN, OCN, Dawn Hayes, PT, PhD, GCS, Donna Meyer, BSN, MS, Bryan Miller, MSW, LCSW, OSW-C, Amy Sickles, PA-C, Mildred Nunez Jones, BA, CTR, Hiba Tamim, MD
The Academy of Oncology Nurse & Patient Navigators (AONN+) promotes the goal to share best practices for survivorship and to address the question “Does the Survivorship Care Plan (SCP) meet patient goals?” (Staci Oertle, RN, MSN, APN, AOCNP, AONN+ Survivorship Committee).
With the increasing cancer survivor population comes the need to develop recommendations about how to optimally care for these survivors.
Caitlin Mason, PhD, Jennifer Haase Morris, MBA, Marlee Fisher, MPH, Patti Migliore Santiago, MAOM, Peggy Hannon, PhD, MPH
Survivorship care recommendations exist to support a large and growing population of cancer survivors, yet little is known about survivors’ ongoing unmet needs.
Katie Narvarte, LMSW, OSW-C, OPN-CG, Emily Gentry, BSN, RN, HON-ONN-CG, OCN, Jordan Henderson, BSN, RN, OCN, ONN-CG, Cristina Laviada, RN, BSN, Mike Ashworth, PhD
In 2005, the Institute of Medicine published “From Cancer Patient to Cancer Survivor: Lost in Transition.” The report highlights the long-term medical and psychosocial consequences of cancer treatment and provides a foundation for survivorship programs today.
Thoracic surgeons remain involved with the long-term care of their cancer patients, usually in surveilling for recurrence. However, with an increasing survivor population, little is known on their other supportive needs.
Arin Ahlum Hanson, MPH, Lori Ranallo, RN, MSN, APRN-BC, CBCN, Karen Werner Carera, PhD, Betsy Smither, MPH, CHES, Jennifer Reynolds, MPH, CHES, Ingrid Mapanao
Women diagnosed with breast cancer before age 45 face unique survivorship challenges, including early menopause, late effects of treatment, psychosocial distress, and sex and intimacy changes.
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in breast cancer and can promote tumor growth, progression, and resistance to anticancer therapies such as endocrine therapy (ET).
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
Multiple tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 ATP-binding site are available for treating chronic myeloid leukemia (CML).
The COMBI-AD trial demonstrated that adjuvant treatment with dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF-mutant melanoma significantly reduced the risk of melanoma recurrence vs placebo (PBO).
Dirk Schadendorf, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, MD, PhD, Reinhard Dummer, MD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
Adjuvant treatment (tx) of resected stage III BRAF-mutant melanoma with dabrafenib + trametinib (D+T) significantly reduced the risk of recurrence vs placebo (PBO).
Karwyn S. Gustafson, RN, MSN, Francisco J. Esteva, MD, PhD, Peter Jiang, MD, J. Thaddeus Beck, MD, Dennis J. Slamon, MD, PhD
Ribociclib combined with an aromatase inhibitor has been shown to significantly prolong progression-free survival (PFS) in premenopausal and postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) who had not been treated previously for ABC.
Endocrine therapy (ET) is an established treatment for premenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC). MONALEESA-7 (NCT02278120) was the first phase 3 randomized trial of a cyclin-dependent kinases 4 and 6 inhibitor (ribociclib) + ET in premenopausal women with HR+/HER2− ABC without prior ET for ABC.
Andrea Ardizzoni, Anna F. Farago, Akin Atmaca, Emiliano Calvo, Fiona Taylor, Bryan Bennett, Giovanni Selvaggi, Anne Pieters, John R. Penrod, Yong Yuan, D. Ross Camidge
CheckMate 032 (NCT01928394) is an open-label, phase 1/2 trial evaluating the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced or metastatic solid tumors. In this study, nivolumab alone or in combination with ipilimumab showed durable responses, encouraging survival, and manageable safety in patients with small cell lung cancer (SCLC) that progressed after ≥1 previous platinum-containing regimens.
Megan Andersen, NP, Tolu Adewuya, MMedSci, PhD, CCRC, Jianling Li, MS, Zeena Salman, BS, Israel Arango-Hisijara, MD, Leonard T. Heffner, MD, Jeffrey V. Matous, MD
Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) that has demonstrated activity in relapsed Waldenström’s macroglobulinemia (WM). Single-agent ibrutinib is approved in the United States and Europe for WM.
Julie Prettyman, RN, BSN, CCRC, John A. McLane, PhD, Stuart N. Atkinson, MB, ChB, Allison Tyler, RN, BSN, OCN, CCRP, Deborah M. Boldt-Houle, PhD
In prostate cancer therapy, achieving and maintaining effective testosterone (T) suppression to the level attained with surgical castration is the cornerstone of androgen deprivation therapy (ADT).
Palbociclib is the first-in-class cyclin-dependent kinase 4/6 inhibitor approved in the United States in combination with an aromatase inhibitor (AI) or fulvestrant for treating patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (mBC) as initial or later-line endocrine therapy. More than 80,000 patients have been treated in the United States with palbociclib since its approval in February 2015, but data on real-world palbociclib utilization are limited.
Edythe M. Greenberg, PhD, RN, FNP-BC, Jillian Settlemire, RN, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, Tony Lin, PharmD, Steven Coutre, MD, Jan Berger, MD, PhD
Ibrutinib is a first-in-class, once-daily inhibitor of BTK approved in the United States for treatment of CLL/SLL. RESONATE-2 is a phase 3 study comparing first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary results (median follow-up, 18.4 months) demonstrated ibrutinib reduced risk of progressive disease (PD) or death by 84% (Burger, 2015).
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512